The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine ... and Eli Lilly’s Trulicity (dulaglutide). The two treatments are GLP-1 receptor agonists, which ...
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback